Marie-Antoinette S.
- Country
- France
- Department
- Vascular
Research Overview
- Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE
- Effect of One-Year versus One-Month Dual Antiplatelet Therapy Comprising Aspirin and Clopidogrel on Outcomes in Patients with Chronic Limb-Threatening Ischemia After Revascularization
- Efficacy and Safety of REGN7508 for Primary Prophylaxis of Cancer-Associated Thrombosis in Patients with Solid Tumors Undergoing Cancer Treatment
Data & Insights
Has run more than one trial at 193 of 705 partner sites.
Specializations
Cardiovascular Disease Management
This investigator specializes in treating atherosclerotic cardiovascular disease (ASCVD), with particular focus on preventive therapies for cardiovascular events. Their research explores innovative approaches to reduce the risk of cardiovascular death, heart attacks, and strokes in high-risk patients.
- Lipid Management
- Cardiovascular Risk Reduction
- Preventive Cardiology
Thrombosis Research
The investigator conducts research in venous thromboembolism (VTE) management, with particular expertise in treating cancer-associated thrombosis. Their work includes evaluation of antithrombotic therapies and investigation of optimal treatment approaches for patients requiring both anticoagulation and antiplatelet therapy.
- Cancer-Associated Thrombosis
- Anticoagulation Strategies
- Bleeding Risk Management
Peripheral Vascular Disease
The investigator focuses on treating peripheral arterial disease, particularly addressing intermittent claudication. Their research explores therapeutic interventions to improve walking capacity and quality of life in affected patients.
- Walking Capacity Enhancement
- Vascular Function
- Exercise Performance
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.